USFDA Classifies Cipla's Goa Facility Inspection as Voluntary Action Indicated (VAI)
Cipla Ltd has received the classification from the United States Food and Drug Administration (USFDA) regarding the routine Good Manufacturing Practices (cGMP) inspection conducted at its manufacturing facility in Verna, Goa. The USFDA classified the inspection as Voluntary Action Indicated (VAI).The investigation covered both the routine cGMP inspection and a Pre-Approval Inspection (PAI) at the company's facility located in Verna, Goa, India. These inspections took place between April 6 and April 17, 2026. The USFDA issued its classification via communication dated June 10, 2026.
CIPLA Stock Price Movement
Shares of Cipla Limited are edging higher to ₹1385.9 as of 2:05 PM today, after gaining ₹8.90 in live trading. The stock has seen heavy session activity with 416,392 shares traded so far into the market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.